Table 3.

Adverse Event and Billing Outcomes

Endpoint	Outcome (n = 93)
Adverse events reported at time of injection, n (%)	4 (4.3)
Hypersensitivity or anaphylaxis, n (%)	0 (0)
Infection other than COVID-19, n (%)	0 (0)
Injection site reaction, n (%)	0 (0)
Death, n (%)	0 (0)
Gastrointestinal distress, n (%)	0 (0)
New pulmonary disorder or cardiac disorder, n (%)	0 (0)
Syncope, n (%)	4 (4.3)
Headache, n (%)	0 (0)
Adverse events reported at follow-up phone call, n (%)	9 (9.7)
Hypersensitivity/anaphylaxis, n (%)	1 (1.1)
Infection other than COVID-19, n (%)	1 (1.1)
Injection site reaction, n (%)	4 (4.3)
Death, n (%)	0 (0)
Gastrointestinal distress, n (%)	5 (5.4)
New pulmonary or cardiac disorder, n (%)	1 (1.1)
Syncope, n (%)	0 (0)
Headache, n (%)	2 (2.2)
Patient reported hospitalization at follow-up phone call, n (%)	9 (9.7)
Patient reported returning to normal daily activity at follow-up phone call, n (%)	77 (82.8)
Billing for pharmacy services successful, n (%)	77 (82.8)
Commercial insurance, n (%)	56 (60.2)
Medicare, n (%)	22 (23.7)
Medicaid, n (%)	8 (8.6)
Cash, n (%)	7 (7.5)